However, in the last decade, SOX2 has been characterized beyond its role in embryonic stem cells, and evidence has shown that there may be a therapeutic benefit in targeting SOX2 to reduce its probable tumor-initiating capacity in various cancers. This evidence concerns the gene SOX2 and cancer.